Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 8c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.59), $0.08 better than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• RBC bullish on Kraft Heinz, sees return to growth in 2027
• SEC Issues Guidance to Tokenize Stocks After Clarity Act Failure, Robinhood (HOOD) Gains
• TD Cowen Boston Scientific (BSX): 'We Maintain Our Constructive 2027-Based View'